The Q2 revenue guidance of 10-15% YoY growth and record consumables unit volumes suggest underlying demand is improving, but the GAAP operating loss and declining gross margin are concerning. Watch for the May 13 conference call for color on margin trajectory and whether the operating loss trend reverses in Q2. The stock's small market cap ($138M) amplifies sensitivity to these mixed signals.
Price Chart
Executive Summary
SANUWAVE Health reported Q1 2026 revenue of $9.6M (+3.1% YoY), in line with guidance, but swung to an operating loss of $1.1M from operating income of $0.6M a year ago. The company guided Q2 2026 revenue of $11.1-11.6M (+10-15% YoY) and reiterated full-year 2026 revenue guidance of $51-55M (+16-25% YoY). Despite the revenue growth, the GAAP operating loss and declining gross margin (77.3% vs 79.0%) signal deteriorating profitability, while the strong sequential consumables unit growth and raised Q2 guidance provide some positive offset.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $9.6M, up 3.1% YoY from $9.3M, in line with 3-10% guidance
- GAAP operating loss of $1.1M vs operating income of $0.6M in Q1 2025 ($1.7M swing)
- GAAP net loss $1.4M vs $6.1M in Q1 2025 (improvement driven by absence of $4.9M derivative loss)
- Gross margin 77.3% vs 79.0% YoY, pressured by lower pricing on reseller sales
- Ultramist consumables revenue $6.7M, up 15% YoY and 3% sequentially; unit volumes set all-time record
- Adjusted EBITDA $1.1M vs $2.3M in Q1 2025
- Q2 2026 revenue guidance $11.1-11.6M (+10-15% YoY); full-year 2026 revenue guidance $51-55M (+16-25% YoY) reiterated
- Cash and cash equivalents $10.8M at March 31, 2026, down from $12.0M at Dec 31, 2025
- Operating cash flow positive $0.4M vs negative $1.5M in Q1 2025
Financial Impact
Revenue growth of 3.1% YoY to $9.6M, but GAAP operating income swung from +$0.6M to -$1.1M; Q2 guidance implies ~$11.1-11.6M revenue
Risk Factors
- GAAP operating loss may persist if gross margin continues to compress and operating expenses grow faster than revenue
- Revenue concentration in Ultramist (100% of revenue) creates single-product risk
- Cash burn: cash declined $1.2M in Q1 to $10.8M, though operating cash flow turned positive
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293516 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $4.65 $4.70 | ▼ −1.08% | ▲ +0.13% | $5.15 (−10.75%) |
Aug 6, 2026 11w ago | 8-K | $5.88 $4.74 | ▲ +19.39% | ▲ +19.79% | $5.15 (+12.41%) |
Aug 6, 2026 11w ago | Press Release | $5.88 $4.74 | ▲ +19.39% | ▲ +19.79% | $5.15 (+12.41%) |
Jul 30, 2026 12w ago | Press Release | $6.17 $5.88 | ▼ −4.70% | ▼ −8.21% | $5.15 (−16.53%) |
Jun 16, 2026 18w ago | 8-K | $8.51 $8.20 | ▲ +3.64% | ▲ +1.41% | $5.15 (+39.48%) |
Jun 16, 2026 18w ago | Press Release | $8.51 $8.20 | ▲ +3.64% | ▲ +1.41% | $5.15 (+39.48%) |
Jun 11, 2026 19w ago | Institutional Cluster | $14.69 $9.09 | ▼ −38.12% | ▼ −38.55% | $5.15 (−64.94%) |
May 12, 2026 23w ago | Press Release | $18.94 $16.69 | ▼ −11.88% | ▼ −10.72% | $5.15 (−72.81%) |
May 6, 2026 24w ago | Press Release | $16.65 $18.94 | ▲ +13.75% | ▲ +12.25% | $5.15 (−69.07%) |
Apr 16, 2026 27w ago | 8-K | $20.61 $18.70 | ▼ −9.27% | ▼ −9.82% | $5.15 (−75.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers